BioAtla, Inc. (NASDAQ:BCAB) Sees Large Decline in Short Interest

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 2,697,341 shares, a decrease of 59.2% from the January 29th total of 6,612,587 shares. Currently, 4.8% of the company’s stock are short sold. Based on an average trading volume of 3,975,081 shares, the days-to-cover ratio is currently 0.7 days. Based on an average trading volume of 3,975,081 shares, the days-to-cover ratio is currently 0.7 days. Currently, 4.8% of the company’s stock are short sold.

Institutional Trading of BioAtla

Institutional investors and hedge funds have recently bought and sold shares of the stock. Woodline Partners LP bought a new position in shares of BioAtla during the 1st quarter valued at about $26,000. Sheets Smith Investment Management bought a new position in BioAtla during the third quarter valued at approximately $46,000. ADAR1 Capital Management LLC bought a new position in BioAtla during the fourth quarter valued at approximately $104,000. Susquehanna International Group LLP grew its holdings in BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after buying an additional 177,760 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares during the last quarter. 77.23% of the stock is currently owned by institutional investors.

BioAtla Trading Up 4.5%

NASDAQ BCAB traded up $0.01 on Friday, hitting $0.25. 2,023,042 shares of the company traded hands, compared to its average volume of 2,780,937. The business’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.58. BioAtla has a 52-week low of $0.13 and a 52-week high of $1.43. The company has a market capitalization of $15.74 million, a price-to-earnings ratio of -0.22 and a beta of 1.10.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BCAB shares. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a research note on Friday, January 9th. Rodman & Renshaw started coverage on BioAtla in a report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.